...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis an econometric model
【24h】

Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis an econometric model

机译：干扰素-β-1a治疗复发缓解型多发性硬化症的长期成本效益计量经济模型

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate the cost effectiveness of subcutaneous interferon-beta-la (IFNbeta-la) 44mug three times weekly in relapsing-remitting multiple sclerosis (RRMS) using an econometric model.Methods: Data on RRMS patients treated with IFNbeta-la 22 or 44mug subcutane-ously three times weekly or placebo for up to 4 years were obtained from the Prevention of Relapses and disability by Interferon-beta-la Subcutaneously in Multiple Sclerosis (PRISMS) study. The area under the Expanded Disability Status Scale (EDSS) score-time curve was used as a measure of disability and the effectiveness of therapy was expressed as EDSS-months of disability prevented. Costs were calculated for the UK and France, and results were projected to 10 and 20 years using a time series regression model.Results: Over 10 years, treatment with IFNbeta-la 44mug subcutaneously three times weekly prevented 121 EDSS-months of additional disability at a cost of Euros (EURO)732 each (year of costing 2000). Over 20 years, 321 EDSS-months were saved at a cost of EURO359 per month (year of costing 2000).Conclusion: This analysis indicated that IFNbeta-la 44mug subcutaneously three times weekly is cost effective in RRMS and that treatment becomes increasingly cost effective over time.
机译：目的：使用计量经济学模型评估每周三次皮下注射干扰素-β-1a（IFNbeta-la）44杯在复发-缓解型多发性硬化症（RRMS）中的成本效益。方法：采用IFNbeta-la 22或从多发性硬化症的皮下注射干扰素-β-la预防复发和残疾的研究中，每周三次服用44杯皮下药或长达4年的安慰剂。扩展残疾状况量表（EDSS）评分-时间曲线下的面积用作残疾的量度，治疗效果表示为EDSS预防月数。计算了英国和法国的成本，并使用时间序列回归模型将结果预测为10年和20年。结果：在过去10年中，IFNbeta-la 44mug每周皮下治疗3次，预防了121 EDSS月的额外残疾每个费用为732欧元（2000年费用）。在20年的时间里，每月节省321 EDSS，费用为EURO359（2000年）。结论：这项分析表明，IFNbeta-la 44皮下每周3次皮下治疗RRMS具有成本效益，并且治疗变得越来越具有成本效益随着时间的推移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号